African Trypanosomiasis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

African Trypanosomiasis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H1 2015', provides an overview of the African Trypanosomiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for African Trypanosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for African Trypanosomiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for African Trypanosomiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the African Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the African Trypanosomiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
African Trypanosomiasis Overview 6
Therapeutics Development 7
Pipeline Products for African Trypanosomiasis - Overview 7
Pipeline Products for African Trypanosomiasis - Comparative Analysis 8
African Trypanosomiasis - Therapeutics under Development by Companies 9
African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 10
African Trypanosomiasis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
African Trypanosomiasis - Products under Development by Companies 13
African Trypanosomiasis - Products under Investigation by Universities/Institutes 14
African Trypanosomiasis - Companies Involved in Therapeutics Development 15
Anacor Pharmaceuticals, Inc. 15
Sanofi 16
Scynexis, Inc. 17
African Trypanosomiasis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
AN-4169 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AN-5568 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fexinidazole - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LH-7 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Peptides for Sleeping Sickness - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules for African Trypanosomiasis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules for Malaria and African Trypanosomiasis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules for Protozoal Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Sleeping Sickness - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
African Trypanosomiasis - Recent Pipeline Updates 38
African Trypanosomiasis - Dormant Projects 39
African Trypanosomiasis - Discontinued Products 40
African Trypanosomiasis - Product Development Milestones 41
Featured News & Press Releases 41
Mar 12, 2012: Anacor Announces Commencement of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 41
Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate to Combat Sleeping Sickness 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables
Number of Products under Development for African Trypanosomiasis, H1 2015 7
Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
African Trypanosomiasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 15
African Trypanosomiasis - Pipeline by Sanofi, H1 2015 16
African Trypanosomiasis - Pipeline by Scynexis, Inc., H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
African Trypanosomiasis Therapeutics - Recent Pipeline Updates, H1 2015 38
African Trypanosomiasis - Dormant Projects, H1 2015 39
African Trypanosomiasis - Discontinued Products, H1 2015 40